

Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Commwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Steffe  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugaisky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Garrett  
Heidi L. Kraus  
Edward W. Yee  
Albert L. Ferro\*  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Eldora Ellison Floyd  
Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beaton  
Kimberly N. Reddick

Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham  
Christine M. Lhulier  
Rae Lynn Pregarman  
Jane Shershenovich\*  
Lawrence J. Carroll\*  
George S. Bardmesser  
Daniel A. Klein\*  
Jason D. Eisenberg  
Michael D. Specht  
Andrea J. Kamage  
Tracy L. Muller  
Jon E. Wright\*  
LuAnne M. Yuricek\*  
John J. Figueroa

Ann E. Summerfield  
Tiera S. Coston\*  
Aric W. Ledford\*  
  
**Registered Patent Agents\***  
Karen R. Markowicz  
Nancy J. Leith  
Helene C. Carlson  
Gaby L. Longworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Mary B. Tung  
Katrina Y. Pei Quach  
Bryan L. Skelton  
Robert A. Schwartzman  
Timothy A. Doyle  
Jennifer R. Mahalingappa

Teresa A. Colella  
Jeffrey S. Lundgren  
Victoria S. Rutherford  
Eric D. Hayes

**Of Counsel**  
Kenneth C. Bass III  
Evan R. Smith

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Practice Limited to  
Federal Agencies

November 10, 2003

**WRITER'S DIRECT NUMBER:**  
(202) 772-8619

**INTERNET ADDRESS:**  
schwartz@skgf.com

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Art Unit 1644**

Re: U.S. Utility Patent Application  
Appl. No. 09/920,332; filed August 2, 2001  
For: **Method of Identifying Immunosuppressive Agents**  
Inventors: Kasibhatla *et al.*  
Our Ref: 1735.0470001/RWE/ALS

**RECEIVED**

NOV 19 2003

TECH CENTER 1600/2900

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Fee Transmittal (Form PTO/SB/17);
2. Amendment And Reply Under 37 C.F.R. § 1.111, with Exhibits A and B;
3. Second Supplemental Information Disclosure Statement;
4. Form PTO-1449 and accompanying (2) references;
5. Return postcard; and
6. Credit Card Payment Form PTO-2035 for \$180.00 to cover the fee for submission of an Information Disclosure Statement (37 C.F.R. § 1.17(p)).


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents  
November 10, 2003  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Aaron L. Schwartz  
Agent for Applicants  
Registration No. 48,181

ALS/dab  
::ODMA\MHODMA\SKGF\_DC1;197523;1  
Enclosures



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kasibhatla *et al.*

Appl. No. 09/920,332

Filed: August 2, 2001

For: **Method of Identifying  
Immunosuppressive Agents**

Confirmation No. 5774

Art Unit: 1644

Examiner: Huynh, P. N.

Atty. Docket: 1735.0470001/RWE/ALS

**Second Supplemental Information Disclosure Statement**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**RECEIVED**

NOV 19 2003

TECH CENTER 1600/2900

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' previously filed Information Disclosure Statements, in connection with the above-captioned application. A copy of each document is also provided.

The Examiner's attention is directed to co-pending U.S. Patent Application No. 09/947,387, filed September 7, 2001, which is cited as published U.S. Application No. 2002/0150885 A1 (document **AJ3**); and co-pending U.S. Patent Application No. 10/046,548, filed January 16, 2002, which is cited as published U.S. Application No. 2003/0027229 A1 (document **AK3**). The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to these applications now or upon issuance of the above captioned application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not

in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.


Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. The \$180.00 fee under 37 C.F.R. § 1.17(p) is included in the attached Form PTO-2038 Credit Card Payment Form.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Aaron L. Schwartz  
Agent for Applicants  
Registration No. 48,181

Date: November 10, 2003

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



FORM PTO-1449

SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1735.0470001/RWE/ALSAPPLICATION NO.  
09/920,332APPLICANTS  
Kasibhatla et al.FILING DATE  
August 2, 2001GROUP  
1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ3	2002/0150885-A1	10/17/2002	Weber et al.			09/07/2001
	AK3	2003/0027229-A1	02/06/2003	Kasibhatla et al.			01/16/2002

RECEIVED  
NOV 19 2003  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.  
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.